Home
The Biology of Ageing: From Hallmarks to Drugs
Barnes and Noble
The Biology of Ageing: From Hallmarks to Drugs
Current price: $150.00
Barnes and Noble
The Biology of Ageing: From Hallmarks to Drugs
Current price: $150.00
Size: Hardcover
Loading Inventory...
*Product information may vary - to confirm product availability, pricing, shipping and return information please contact Barnes and Noble
The Biology of Ageing: From Hallmarks to Drugs
provides a series of reviews covering multiple aspects of the translational pipeline as interventions in the biology of ageing itself become a clinical reality. New chapters cover Cellular senescence and NAD+: what are the links?, Biomarker for ageing: potential and pitfalls, What chemists offer to ageing research, You are what you eat – or are you? Exploring dietary versus topical anti-oxidants in skin ageing, Clinical trials: A simple guide for gerontologists, Towards an ethical framework for geroscience, and more.
The book explores links between known ageing mechanisms and new interventions, agents and actions at the nutraceutical-drug divide, the challenges and opportunities provided by biomarkers and chemistry- biology interface and lastly the ethical and operational challenges of clinical trials in the age of translational geroscience.
provides a series of reviews covering multiple aspects of the translational pipeline as interventions in the biology of ageing itself become a clinical reality. New chapters cover Cellular senescence and NAD+: what are the links?, Biomarker for ageing: potential and pitfalls, What chemists offer to ageing research, You are what you eat – or are you? Exploring dietary versus topical anti-oxidants in skin ageing, Clinical trials: A simple guide for gerontologists, Towards an ethical framework for geroscience, and more.
The book explores links between known ageing mechanisms and new interventions, agents and actions at the nutraceutical-drug divide, the challenges and opportunities provided by biomarkers and chemistry- biology interface and lastly the ethical and operational challenges of clinical trials in the age of translational geroscience.